Big technology names drove the Nasdaq Composite to a weekly gain as the Dow Jones Industrial Average and Russell 2000 both closed the week lower.
The Dow finished at 51,094.96, up 0.33% on Friday but down 1.42% for the week, with an RSI14 of 38.1 signaling a weakening trend.
The S&P 500 ended the week at 7,719.34, gaining 0.69% on the day but slipping 0.31% for the week despite a strong Friday session.
The Nasdaq Composite jumped 1.18% on Friday to close at 27,188.02, posting a weekly gain of 0.44% as chip and software stocks led the charge.
The Russell 2000 rose 0.97% on the day to 2,833.74 but finished the week slightly lower, down 0.13%, reflecting a narrow and uneven rally as the new quarter began.
The CBOE Volatility Index fell to 15.58, declining 0.81 on the day and 0.49 for the week, as market anxiety eased heading into the weekend.
WTI crude oil dropped 2.48% on Friday and 2.19% for the week to $90.57 a barrel, while gold eased 0.85% on the day to $4,166.60 an ounce.
The US 10-year Treasury yield rose 2 basis points on the day and 8 basis points for the week to 5.26%, while the euro weakened 0.64% against the dollar on Friday.
Several companies made headlines this week with contract awards, guidance updates, and acquisition activity across defense, healthcare, metals, real estate, and biotech sectors.
Raytheon, an RTX (NYSE: RTX) business, secured a five-year contract with two additional option years valued at up to $24.4 billion for Standard Missile-6 interceptors to support the U.S. Navy.
“SM-6’s multi-mission capability is vital to our customer, and Raytheon is intensely focused on meeting the demand,” said Phil Jasper, Raytheon President.
RTX described SM-6 as the only combat-proven weapon capable of anti-air warfare, anti-surface warfare, and ballistic missile defense, and said it has invested in workforce growth and automation.
Integra LifeSciences Holdings Corporation (Nasdaq: IART) provided preliminary third quarter results, expecting revenue of approximately $410 million to $412 million and adjusted EPS of $0.55 to $0.59.
“Our third quarter results were impacted by the July flooding event at our Cincinnati facility,” said Stuart Essig, Chairman and Chief Executive Officer.
Integra lowered its full-year 2026 revenue outlook to $1.634 billion to $1.654 billion and cut adjusted EPS guidance to $2.30 to $2.40, while maintaining its operating cash flow forecast of $190 million to $200 million.
Trilogy Metals Inc. (NYSE American: TMQ) reported a cash balance of $31.2 million as of August 31, 2026, and announced the closing of a $35.6 million strategic equity investment from the Department of War on September 11, 2026.
“The third quarter and the weeks that followed have been transformational for Trilogy Metals,” said Tony Giardini, President and CEO.
Phillips Edison & Company, Inc. (Nasdaq: PECO) reaffirmed its full-year 2026 earnings guidance and raised its gross acquisitions target to $600 million to $700 million after acquiring $459.7 million in assets year to date.
“We’re pleased to reaffirm our guidance for full year 2026 Core FFO per share growth, which reflects 6.2% year-over-year growth at the midpoint,” said Jeff Edison, Chairman and Chief Executive Officer.
Axogen, Inc. (Nasdaq: AXGN) completed its acquisition of BioCircuit Technologies, adding NerveTape, described as the first FDA cleared device for sutureless peripheral nerve repair, and expects the deal to contribute approximately $34 million to 2027 revenue.
